

Naloxone Performance Measures (Background Information) - January 28, 2019

Outcome Measure	Numerator	Denominator	Comments
Clinical Improvement			
<p>1) % of Patients with initial pulse ox \leq 94%, increased after EMS initiated care</p> <p><i>(This measure was ranked #1 of the 3 clinical improvement measures)</i></p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD with initial pulse ox of 94% or less AND had a final pulse ox of > 94%</p> <p>Distinct eRecord.01 Where Chronologically_Last(SpO2) > 94</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD with initial pulse ox of 94% or less</p> <p>(eSituation.11 or eSituation.12 = “T40.0X4“, “T40.2X4“, “T40.4X4“, “T40.1X4”) and Chronologically_First(SpO2) < 94</p>	<p>RH: Complex Measure calculation requiring Vital Sign Aggregation at the level of the patient but feasible.</p>
<p>2) % of patients with GCS of less than 15 improved after EMS initiated care</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD with initial GCS less than 15 AND had a final GCS higher than initial</p> <p>Distinct eRecord.01 Where Chronologically_Last (GCS_Total) > 15</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD with initial GCS less than 15</p> <p>eSituation.11 or eSituation.12 = “T40.0X4“, “T40.2X4“, “T40.4X4“, “T40.1X4”) and Chronologically_First (GCS_Total) < 15</p>	<p>RH: Complex Measure calculation requiring Vital Sign Aggregation at the level of the patient but feasible.</p>
<p>3) % of patients with respiratory rate less than 10 increased to 12 or more after EMS initiated care</p> <p><i>(Ranked as #2 clinical improvement measures)</i></p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD with initial RR less than 10 AND had a final RR equal or greater than 12</p> <p>Distinct eRecord.01 Where Chronologically_Last (RR) > 15</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD with initial RR less than 10</p> <p>eSituation.11 or eSituation.12 = “T40.0X4“, “T40.2X4“, “T40.4X4“, “T40.1X4”) and Chronologically_First (RR) < 10)</p>	<p>RH: Complex Measure calculation requiring Vital Sign Aggregation at the level of the patient but feasible.</p>
Identification / Treatment	Numerator	Denominator	Comments

<p>4) % of patients with signs and symptoms of possible opioid OD who did not receive naloxone (under treatment)</p> <p>Probably most important to know when patient was under treated</p>	<p># of Patients with altered LOC (GCS less than 15), and respiratory depression (RR less than 10), and/or pin point pupils, AND did not receive intervention of naloxone</p> <p><i>Need to verify language related to pinpoint pupils</i></p>	<p># of Patients with altered LOC (GCS less than 15), and respiratory depression (RR less than 10), and/or pin point pupils</p>	<p>Potentially a balancing measure</p> <p>RH: This is possible with the data but assessment data for pupils inconsistent- if denominator is an “and” between the pupils and these other indicators it won’t be many patients.</p>
<p>5) % of patients treated with Naloxone as suspected opioid overdose but did not exhibit signs and symptoms (over treatment)</p> <p>Measure added to address naloxone tunnel vision</p>	<p># of patients who received naloxone AND DID NOT HAVE altered LOC (GCS less than 15), and respiratory depression (RR less than 10), and/or pin point pupils, OR Primary or Secondary Impression of (suspected) opioid OD</p> <p>or (eSituation.11 or eSituation.12 = (“T40.0X4“, “T40.2X4“, “T40.4X4“, “T40.1X4”))</p>	<p># of patients who received naloxone</p>	
<p>6) % of patients who were treated as suspected naloxone overdose and exhibited signs and symptoms (appropriate treatment)</p> <p>Measure added to balance other 2 measures</p>	<p># of patients who received naloxone AND had altered LOC (GCS less than 15), and respiratory depression (RR less than 10) and/or pin point pupils; OR Primary or Secondary Impression of (suspected) opioid OD</p>	<p># of Patients with altered LOC (GCS less than 15), and respiratory depression (RR less than 10), and/or pin point pupils; OR Primary or Secondary Impression of (suspected) opioid OD</p>	
<p>Patient Disposition</p>	<p>Numerator</p>	<p>Denominator</p>	<p>Comments</p>

<p>7) % of patients treated with Naloxone refused transport</p> <p>Could be considered an outcome measure since condition must have improved to be able to refuse transport.</p> <p>NEW QUESTION- Do protocols allow refusals of suspected opioid OD due to the potential of deterioration since duration of naloxone is shorter than most opioids?</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD AND who received Naloxone either prior to EMS arrival or by EMS AND signed refusal for ambulance transport</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD and Naloxone was administered either Prior to EMS arrival or by EMS</p> <p>eSituation.11 or eSituation.12 = “T40.0X4“, “T40.2X4“, “T40.4X4“, “T40.1X4”)</p>	<p>RH: Easy</p>
<p>% of patients transported to hospital by ambulance</p> <p>Determined to be more of Informational metric and recommended we do not include</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD AND who were transported to hospital by ambulance</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD</p> <p>eSituation.11 or eSituation.12 = “T40.0X4“, “T40.2X4“, “T40.4X4“, “T40.1X4”)</p>	<p>Possible dispositions include refused, transported, deceased (?)</p> <p>RH: Easy</p>

Supporting Measure	Numerator	Denominator	Comments
<p>8) % of patients received airway support prior to administration of Naloxone</p> <p><i>This measure was determined to be not as important as time to initiate assisted airway measure</i></p>	<p># where artificial assisted airway ventilation intervention preceded Naloxone intervention</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD</p> <p>eSituation.11 or eSituation.12 = “T40.0X4“, “T40.2X4“, “T40.4X4“, “T40.1X4”)</p>	<p>RH: Easy</p>
<p>% of patients received Naloxone within x (7) minutes from the time EMS arrived on scene</p> <p>9) % of patients received artificial assisted airway ventilation within 5 minutes from first responding EMS unit at scene time.</p> <p>This measure was ranked as #1 of Support measures</p>	<p># with At-Scene time to assisted airway intervention = 5 min or less</p>	<p># of Patients with primary or secondary impression of (suspected) opioid OD</p> <p>eSituation.11 or eSituation.12 = “T40.0X4“, “T40.2X4“, “T40.4X4“, “T40.1X4”)</p>	<p>DV: On-scene versus at-patient because not all agencies capture at-patient time. At-scene captured by CAD which automatically imports into ePCR. Five minutes chosen based on theory that on average</p>

			<p>it takes EMS 2-3 minutes to access patient once on scene and then allows up to 2 more minutes to begin ventilations.</p> <p>RH: Easy</p>
<p>% of patients receive Naloxone via IN route during care</p> <p><i>Why focus on route? Some providers do not have IV as option. Group recommends not including this one.</i></p>	<p># receive Naloxone via IN</p>	<p># of Patients with primary impression of (suspected) opioid OD</p> <p>eSituation.11 or eSituation.12 = "T40.0X4", "T40.2X4", "T40.4X4", "T40.1X4")</p>	<p>Does it matter if they started with IN?</p> <p>RH: Easy</p>
<p>10) % of patients who exhibit adverse effects (agitation, vomiting, aspiration) after administration of Naloxone.</p> <p>This measure was added to capture occurrences of when treatment overshoots the goal of improving hypoxia and mental status (rather than full reversal with adverse reactions and need to re-medicate)</p> <p>Ranked as #2 support measure</p>	<p># of patients who receive naloxone AND exhibit adverse effects (agitation, vomiting, aspiration) after administration of Naloxone</p>	<p># of patients who receive naloxone</p>	

Performance Measures Team

Dr. Peter Taillac, Lead (performance measure development)

Richard Hale, Technical Lead (pseudocode development)

Debbie Vass (performance measure development)

Dr. Ken Williams, PI

Dr. John Lyng, Co-Inv.

Dia Gainor (performance measure development)

Mary Hedges

